SONO 2024

Dados do Trabalho


Título

Efficacy, Safety, and Indications of Exogenous Melatonin in the Autistic Population

Introdução

Exogenous melatonin, a hormone related to sleep and circadian rhythm regulation, is currently being studied as a pharmacologic modality in sleep disturbances, especially in individuals diagnosed with Autism Spectrum Disorder (ASD). The incidence of sleep disorders among individuals with ASD is high, and the potential benefit of melatonin in these cases warrants further study.

Objetivo

This paper presents a review of the current scientific evidence regarding the use of exogenous melatonin in autistic individuals, focusing on its efficacy, safety, and dosages compared to other recommended therapies or a placebo.

Métodos

This systematic narrative review followed PRISMA guidelines. The search included scientific articles published in the last 10 years in relation to the terms "Exogenous Melatonin" and "Autism," of which 17 relevant studies were selected. Excluded are researches with animals, plants and case reports,as well as analyses conducted with fewer than twenty participants.

Resultados

The review showed that intervention with melatonin has efficacy by reducing sleep onset latency and increasing the total sleep time, in addition to reducing the number of wake-up instances during the night in children with ASD. The findings suggest that melatonin is generally well-tolerated with minimal adverse effects, such as headaches, dizziness, and daytime drowsiness. There is a variability in individual responses, and long-term safety remains to be investigated.

Conclusões

Exogenous melatonin appears to be an efficacious and well-tolerated treatment method for patients with ASD-associated sleep disorders. Furthermore, research shows that the benefits of pharmacological treatment could be enhanced when in conjunction with behavioral interventions. Constant monitoring and titration in dosage are needed to maximize the therapeutic benefits derived from the medicine. Long-term safety monitoring is required to address concerns, particularly for subgroups of ASD

Palavras -chave

Autism Spectrum Disorder, Exogenous Melatonin, Sleep Disorders

Área

Área Básica

Autores

HELENA RIBEIRO VALENTIM DA ROCHA, Bernardo Almeida Araújo, Bruna Ferreira Soares, Gabriela Fernandes Marinho da Rocha, Ana Beatriz da Costa Pinto Diniz, Pedro Delaroli Correa de Barros